Whitehawk Therapeutics (NASDAQ:WHWK) CFO Scott Giacobello Sells 77,000 Shares of Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CFO Scott Giacobello sold 77,000 shares of Whitehawk Therapeutics stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $3.86, for a total transaction of $297,220.00. Following the completion of the sale, the chief financial officer owned 436,824 shares in the company, valued at approximately $1,686,140.64. This represents a 14.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Trading Down 2.8%

NASDAQ WHWK opened at $4.11 on Friday. The company has a 50-day moving average price of $3.46 and a two-hundred day moving average price of $2.78. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $4.48. The stock has a market cap of $193.99 million, a price-to-earnings ratio of 8.74 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on WHWK shares. Wall Street Zen downgraded shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Citigroup assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective for the company. Finally, JonesTrading started coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several large investors have recently modified their holdings of the stock. Orbimed Advisors LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth $7,915,000. Suvretta Capital Management LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at $7,030,000. Acuta Capital Partners LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at $6,480,000. Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at $5,414,000. Finally, KVP Capital Advisors LP purchased a new position in Whitehawk Therapeutics in the 4th quarter worth about $5,242,000. 52.08% of the stock is owned by institutional investors.

Whitehawk Therapeutics News Summary

Here are the key news stories impacting Whitehawk Therapeutics this week:

• Positive Sentiment: Citizens/JMP initiated coverage with a “Market Outperform” and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
• Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
• Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus “Hold” with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
• Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders’ stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.